Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma

International Journal of Clinical and Experimental Medicine

Volumn 3, Issue 1, 2010, Pages 55-68

  De, Jitakshi ^a   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Classical Hodgkin lymphoma; Diffuse large B cell lymphoma; Morphoproteomics; Survival pathways; Tissue microarray

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE D1; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; S6 KINASE; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR RELA;

ARTICLE; B CELL LYMPHOMA; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FOLLICULAR HYPERPLASIA; HUMAN; HUMAN TISSUE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MICROENVIRONMENT; MORPHOLOGY; NODULAR SCLEROSIS HODGKIN LYMPHOMA; NONHODGKIN LYMPHOMA; PILOT STUDY; PROTEIN EXPRESSION; PROTEOMICS; REED STERNBERG CELL; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SYNCYTIUM; TISSUE MICROARRAY; UPREGULATION;

MAMMALIA;

EID: 77649213114     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Diehl V, Thomas RK and Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004; 5: 19-26.
2. Dancey J and Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2: 296-313.
3. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B and Scheidereit C. Constitutive NFkappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/ Reed-Sternberg cells. Blood 2001; 97: 2798-2807.
4. Brown RE and Kamal NR. p-p70S6K (Thr 389) Expression in nodular sclerosing hodgkin's disease as evidence for receptor tyrosine kinase signaling. Ann Clin Lab Sci 2005; 35: 413-414.
5. Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V and Tesch H. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98: 762-770.
6. Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, Younes M, Vauthey JN, Carbone A and Younes A. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003; 102: 1019-1027.
7. Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ and Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17- demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006; 12: 584-590.
8. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB and Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006; 132: 503-511.
9. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B and Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18: 943-953.
10. Mackenzie GG, Queisser N, Wolfson ML, Fraga CG, Adamo AM and Oteiza PI. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-kappaB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer 2008; 123: 56-65.
11. Keenan C, Thompson S, Knox K and Pears C. Protein kinase C-alpha is essential for Ramos-BL B cell survival. Cell Immunol 1999; 196: 104-109.
12. Brown RE and Nazmi RK. The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications. Ann Clin Lab Sci 2002; 32: 339-351.
13. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005; 2: 337-348.
14. Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA and Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93: 193-200.
15. Aoki J, Inoue A and Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008; 1781: 513-518.
16. Haxhinasto S, Mathis D and Benoist C. The AKTmTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008; 205: 565-574.
17. Lal G and Bromberg JS. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009; 114: 3727-3735.
18. Perez-Rosado A, Artiga M, Vargiu P, Sanchez-Aguilera A, Alvarez-Barrientos A and Piris M. BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas. J Pathol 2008; 214: 498-507.
19. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dorken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-2969.
20. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, Royer HD, Scheidereit C and Dorken B. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/ Reed-Sternberg cells. Blood 1996; 87: 4340-4347.
21. Re D, Kuppers R and Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 2005; 23: 6379-6386.
22. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, Hoffmeyer A, van Deursen J, Sangster MY, Bunting KD, Grosveld GC and Ihle JN. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 1999; 10: 249-259.
23. Schlaifer D, March M, Krajewski S, Laurent G, Pris J, Delsol G, Reed JC and Brousset P. High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. Blood 1995; 85: 2671-2674.
24. Kieslinger M, Woldman I, Moriggl R, Hofmann J, Marine JC, Ihle JN, Beug H and Decker T. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev 2000; 14: 232-244.
25. Van Gool SW, Delabie J, Vandenberghe P, Coorevits L, De Wolf-Peeters C and Ceuppens JL. Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease. Leukemia 1997; 11: 846-851.
26. Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Muller G, Foss HD, Royer HD, Stein H and Dorken B. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999; 94: 2065-2071.
27. Durkop H, Foss HD, Demel G, Klotzbach H, Hahn C and Stein H. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein -Barr virus-transformed lymphoid cells. Blood 1999; 93: 617-623.
28. Poppema S and van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000; 10: 345-350.
29. Zhao X, Qiu W, Kung J, Peng X, Yegappan M, Yen-Lieberman B and Hsi ED. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies. Leuk Res 2008; 32: 275-285.
30. Ding L, Wang HX, Xue M, Zhu L, Liu J, Yan HM, Duan LN and Wang ZD. Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone. Leuk Res 2009; 33: e170-172.
31. Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, Jordan CT, Liesveld J, Fisher RI and Friedberg JW. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008; 19: 1759-1764.
32. Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A and Borchmann P. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica 2007; 92: 568-569.
33. Yamamoto R, Nishikori M, Tashima M, Sakai T, Ichinohe T, Takaori-Kondo A, Ohmori K and Uchiyama T. B7-H1 expression is regulated by MEK/ ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci 2009; 100: 2093-2100.
34. Liu RY, Fan C, Liu G, Olashaw NE and Zuckerman KS. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha -supported proliferation of leukemia and lymphoma cell lines. J Biol Chem 2000; 275: 21086-21093.
35. Tran SE, Holmstrom TH, Ahonen M, Kahari VM and Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 2001; 276: 16484-16490.
36. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F, Aggarwal BB and Younes A. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001; 98: 2784-2790.
37. Duckett CS, Gedrich RW, Gilfillan MC and Thompson CB. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol Cell Biol 1997; 17: 1535-1542.
38. Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P, Zagonel V and Pinto A. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 1995; 85: 780-789.
39. Gruss HJ, Ulrich D, Braddy S, Armitage RJ and Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol 1995; 25: 2083-2089.
40. Doussis-Anagnostopoulou IA, Talks KL, Turley H, Debnam P, Tan DC, Mariatos G, Gorgoulis V, Kittas C and Gatter KC. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease. J Pathol 2002; 197: 677-683.
41. Lahn M, Sundell K and Kohler G. The role of protein kinase C-alpha in hematologic malignancies. Acta Haematol 2006; 115: 1-8.
42. Foss HD, Herbst H, Oelmann E, Samol J, Grebe M, Blankenstein T, Matthes J, Qin ZH, Falini B, Pileri S and et al. Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. Br J Haematol 1993; 84: 627-635.
43. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T and et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994; 263: 89-92.
44. Darnell JE, Jr., Kerr IM and Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
45. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE and Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 2007; 21: 1396-1408.
46. Cao X, Tay A, Guy GR and Tan YH. Activation and association of Stat3 with Src in v-Srctransformed cell lines. Mol Cell Biol 1996; 16: 1595-1603.
47. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J and Jove R. Enhanced DNAbinding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995; 269: 81-83.
48. Bromberg JF, Horvath CM, Besser D, Lathem WW and Darnell JE, Jr. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553-2558.
49. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002; 21: 2000-2008.
50. Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hanakawa Y, Detmar M and Hashimoto K. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 2003; 278: 40026-40031.
51. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D and Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15: 114-123.
52. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H and Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66: 5716-5722.
53. Lamprecht B, Kreher S, Anagnostopoulos I, Johrens K, Monteleone G, Jundt F, Stein H, Janz M, Dorken B and Mathas S. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 2008; 112: 3339-3347.
54. Schreck S, Friebel D, Buettner M, Distel L, Grabenbauer G, Young LS and Niedobitek G. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009; 27: 31-39.
55. Kelley TW, Pohlman B, Elson P and Hsi ED. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007; 128: 958-965.
56. Bladergroen BA, Meijer CJ, ten Berge RL, Hack CE, Muris JJ, Dukers DF, Chott A, Kazama Y, Oudejans JJ, van Berkum O and Kummer JA. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002; 99: 232-237.
57. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J and Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862-2868.
58. Matthias JQ, Misiewicz JJ and Scott RB. Cyclophosphamide in Hodgkin's disease and related disorders. Br Med J 1960; 2: 1837-1840.
59. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, Dreicer R, Bukowski R and Finke JH. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-2157.
60. Elenitoba-Johnson KS, Jenson SD, Abbott RT, Palais RA, Bohling SD, Lin Z, Tripp S, Shami PJ, Wang LY, Coupland RW, Buckstein R, Perez-Ordonez B, Perkins SL, Dube ID and Lim MS. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A 2003; 100: 7259-7264.
61. Davis RE, Brown KD, Siebenlist U and Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874.
62. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L and Staudt LM. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28-40.
63. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, Okamoto M, Morishima Y, Nakamura S and Seto M. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005; 106: 1770-1777.